(05 March 2020) Camostat mesylate- blocks TMPRSS2 activity, which prevents virus entry into host

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4?rss=yes)#secsectitle0035

TMPRSS2 is dispensable for development and homeostasis (Kim et al., 2006) and thus constitutes an attractive drug target. In this context, it is noteworthy that the serine protease inhibitor Camostat mesylate, which blocks TMPRSS2 activity (Kawase et al., 2012; Zhou et al., 2015), has been approved in Japan for human use, but for an unrelated indication